| P2093 | author name string | Yanyan Li | |
| | Tao Zhang | |
| | Peng Zou | |
| | Wenpeng Zhang | |
| | Zhenqing Zhang | |
| | Man Wu | |
| P2860 | cites work | Structure and function of sulfotransferases | Q28200868 |
| | Clinical importance of the cytochromes P450 | Q28208454 |
| | Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33 | Q28285829 |
| | Drug-like properties and the causes of poor solubility and poor permeability | Q30660926 |
| | In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam | Q31035339 |
| | The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery | Q34013578 |
| | Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery | Q34567224 |
| | Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice | Q34913579 |
| | Structural biology and function of solute transporters: implications for identifying and designing substrates | Q35027925 |
| | ABC of oral bioavailability: transporters as gatekeepers in the gut. | Q35591517 |
| | 57 varieties: the human cytochromes P450. | Q35753337 |
| | Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation | Q35993421 |
| | The human intestinal cytochrome P450 "pie". | Q36420382 |
| | Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs | Q36748145 |
| | Bacteria in the intestine, helpful residents or enemies from within? | Q36804240 |
| | Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption | Q57121446 |
| | A Modern View of Excipient Effects on Bioequivalence: Case Study of Sorbitol | Q58869647 |
| | Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35 | Q59215266 |
| | Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3) | Q68885289 |
| | Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical | Q74144243 |
| | Cefpodoxime-proxetil hydrolysis and food effects in the intestinal lumen before absorption: in vitro comparison of rabbit and human material | Q78225581 |
| | Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients | Q80186644 |
| | Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats | Q82798221 |
| | The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers | Q83554317 |
| | Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements | Q84363197 |
| | Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir | Q86170551 |
| | Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients | Q86510501 |
| | Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects | Q87130164 |
| | Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans | Q87289563 |
| | Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective | Q37031077 |
| | Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells | Q37031501 |
| | The effects of pharmaceutical excipients on drug disposition. | Q37058332 |
| | The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). | Q37158694 |
| | Review. Structure and mechanism of ATP-binding cassette transporters | Q37171513 |
| | Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3). | Q37361872 |
| | Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies | Q37371578 |
| | Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters | Q37696476 |
| | The effects of excipients on transporter mediated absorption | Q37736854 |
| | Phase II drug metabolizing enzymes | Q37776407 |
| | Oral drug delivery utilizing intestinal OATP transporters | Q37913584 |
| | Loss of orally administered drugs in GI tract. | Q38130231 |
| | Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity | Q39311415 |
| | Pharmaceutical excipients influence the function of human uptake transporting proteins. | Q39312505 |
| | Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). | Q39684559 |
| | Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients | Q39899409 |
| | Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers | Q39957790 |
| | Effect of excipients on breast cancer resistance protein substrate uptake activity | Q40075189 |
| | Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. | Q40282075 |
| | The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins | Q40645744 |
| | Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes | Q41517289 |
| | Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). | Q41701150 |
| | Enhanced Permeability of Etoposide across Everted Sacs of Rat Small Intestine by Vitamin E-TPGS. | Q41889524 |
| | Identification of a polymorphically expressed member of the human cytochrome P-450III family | Q42003887 |
| | Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry | Q42537547 |
| | Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers | Q42716847 |
| | Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine | Q44196291 |
| | Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid | Q44197333 |
| | Development of synaptic transmission at autonomic synapses in vitro revealed by cytochrome oxidase histochemistry. | Q44330786 |
| | Effect of Various Alcohols on Intestinal Net Water Flux and Theophylline Absorption in Rats | Q44441636 |
| | Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption | Q44729481 |
| | Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo | Q44907372 |
| | Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. | Q46223342 |
| | Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells | Q46359817 |
| | Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). | Q46395975 |
| | Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo | Q46487609 |
| | Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females | Q46502399 |
| | Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration | Q46579125 |
| | Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. | Q46776719 |
| | Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition | Q47689381 |
| | Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. | Q47799418 |
| | Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. | Q48215029 |
| | Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. | Q50967183 |
| | Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. | Q51536172 |
| | Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. | Q52899360 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 830-843 | |
| P577 | publication date | 2016-05-16 | |
| P1433 | published in | The AAPS Journal | Q10695361 |
| P1476 | title | The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update | |
| P478 | volume | 18 | |